Status:
RECRUITING
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Lung Cancer, Non-Small Cell
Immunotherapy
Eligibility:
All Genders
18-79 years
Brief Summary
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy ...
Detailed Description
This observational study aims to comprehensively evaluate the effectiveness and long-term clinical outcomes of neoadjuvant treatment in patients with lung cancer. Central to this investigation are two...
Eligibility Criteria
Inclusion
- Aged between 18 and 79 years;
- Received at least two cycles of neoadjuvant immunotherapy;
- ECOG performance status score of 0;
- Complete clinical information including imaging data available.
Exclusion
- Diagnosed with or suspected active autoimmune diseases;
- Presence of EGFR/ALK sensitive mutations;
- Pregnant or breastfeeding women;
- Previous anti-tumor therapies including chemotherapy or radiotherapy;
- History of organ transplantation or hematopoietic stem cell transplantation;
- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
- Uncontrolled diabetes mellitus;
- Uncontrolled hypertension.
Key Trial Info
Start Date :
April 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 14 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07166003
Start Date
April 20 2025
End Date
April 14 2030
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China